IDXChannel – World Health Organization (WHO) issue a use permit Covid-19 vaccine production of Serum Institute of India, Novavax on Friday (17/12/2021). Thus, the company can send its vaccines for use in vaccination programs.
However, vaksin Novavax currently under European Medicines Agency (EMA) research. The WHO said it would finalize its own assessment of the Novavax vaccine after the EMA issued its recommendations.
According to WHO, the license to use Covavax will provide a significant impetus to increase access to the Covid-19 vaccine, especially in poor countries under the Covax program.
“This list aims to improve access especially in low-income countries, 41 of which are still unable to vaccinate 10 percent of their population, while 98 countries have not reached 40 percent,” the WHO said.
Novavax and the Serum Institute, said that once the vaccine has been researched by the EMA, it will provide more than 1.1 billion doses to support the COVAX vaccination program.
In a late-stage trial in the United States last June, the Novavax vaccine has proven to be more than 90 percent effective against Covid-19, including against various variants of the related coronavirus.
“This vaccine can be used in a variety of contexts, and will provide countries with another important option in their efforts to protect their populations,” said GAVI chief executive Seth Berkley.
(NDA)
– .
